Catechol-oxide-methyltransferase (COMT rs4680:G>A) gene polymorphism does not affect analgesics’ demand after...

Area of Science:

• Genetics
• Pain Management
• Orthopedic Surgery

Background:

• Pain management is crucial for patients with hip osteoarthritis, impacting daily activities and comfort.
• Genetic factors are increasingly recognized for their role in pain perception and analgesic efficacy.
• The catechol-O-methyltransferase (COMT) gene, specifically the rs4680:G>A polymorphism, is a candidate for influencing pain and treatment outcomes.

Purpose of the Study:

• To investigate the association between the COMT rs4680:G>A polymorphism and the demand for analgesics in patients undergoing elective hip replacement.
• To determine if specific COMT genotypes correlate with varying levels of opioid consumption post-surgery.

Main Methods:

• A study involving 196 patients after hip replacement surgery.
• Recording of opioid demand and assessment of analgesic efficacy using a verbal pain intensity scale.
• Analysis of the COMT rs4680:G>A polymorphism via the PCR-RFLP method.

Main Results:

• The distribution of COMT rs4680:G>A genotypes was observed as GA (52.04%), AA (23.98%), and GG (23.98%).
• No significant influence of the studied COMT genotypes on opioid administration was found from the day of surgery up to six days post-operatively.

Conclusions:

• The COMT rs4680:G>A polymorphism is not associated with opioid demand in patients following elective hip replacement.
• These findings indicate that this specific genetic variation may not be a predictive factor for analgesic requirements in this patient population.